Genetic based Biomarkers and Next generation sequencing
Biomarkers have many practices in pharmaceutical analysis & Development. With the recent introduction of high performance instrumentation, macromolecule and sequence arrays and bioinformatics, clinical selections like Drug development and selecting style of treatment are often created with efficiency. However, there's an absence of valid biomarkers to extend the drug development from pre-clinical through all levels of clinical studies. Biomarker in Drug Discovery can even cause development of personalised Medicines.
Biomarkers alter quantitation of the extent to that new medication reach supposed targets, alter projected pathophysiological mechanisms and bring home the bacon clinical outcomes. The Biomarkers challenge is to spot distinctive molecular signatures in complicated biological mixtures that may be unambiguously related to biological events so as to verify novel drug targets and predict drug response. Biomarkers will quantify drug help in primary dodging or disease-modification studies or to separate patient populations in inadequately served regions like neurodegeneration and cancer. Clinically valuable biomarkers ar needed to give notice restrictive and remedial deciding concerning new medication and their signs so as to convey new medications to the correct patients faster than they are these days.
• NGS for the invention of Biomarkers
• MicroRNA sequencing for the prediction of diseases
• SNP as Biomarkers
• Cytogenetic stress Biomarkers
• Genetic-based Biomarkers and NGS in personalised care of Cancer